JO2017B1 - Pharmaceutical formula for infectious residence - Google Patents

Pharmaceutical formula for infectious residence

Info

Publication number
JO2017B1
JO2017B1 JO19982017A JOP19982017A JO2017B1 JO 2017 B1 JO2017 B1 JO 2017B1 JO 19982017 A JO19982017 A JO 19982017A JO P19982017 A JOP19982017 A JO P19982017A JO 2017 B1 JO2017 B1 JO 2017B1
Authority
JO
Jordan
Prior art keywords
gastric residence
pharmaceutical
composition
carbon dioxide
benzamide
Prior art date
Application number
JO19982017A
Other languages
Arabic (ar)
English (en)
Inventor
جيروم بيسي
Original Assignee
سينثيلابو
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سينثيلابو filed Critical سينثيلابو
Application granted granted Critical
Publication of JO2017B1 publication Critical patent/JO2017B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
JO19982017A 1997-04-18 1998-04-18 Pharmaceutical formula for infectious residence JO2017B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704803A FR2762213B1 (fr) 1997-04-18 1997-04-18 Composition pharmaceutique a retention gastrique

Publications (1)

Publication Number Publication Date
JO2017B1 true JO2017B1 (en) 1999-05-15

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
JO19982017A JO2017B1 (en) 1997-04-18 1998-04-18 Pharmaceutical formula for infectious residence

Country Status (19)

Country Link
EP (1) EP0983065A1 (fr)
JP (1) JP2001523241A (fr)
KR (1) KR20010006353A (fr)
CN (1) CN1252720A (fr)
AR (1) AR015586A1 (fr)
AU (1) AU737634B2 (fr)
CA (1) CA2286081A1 (fr)
FR (1) FR2762213B1 (fr)
HU (1) HUP0002455A3 (fr)
IL (1) IL131995A0 (fr)
JO (1) JO2017B1 (fr)
MA (1) MA26482A1 (fr)
NO (1) NO995039L (fr)
NZ (1) NZ500288A (fr)
PE (1) PE68199A1 (fr)
PL (1) PL336273A1 (fr)
TN (1) TNSN98049A1 (fr)
WO (1) WO1998047506A1 (fr)
ZA (1) ZA983258B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
EP1245227A1 (fr) 2001-03-31 2002-10-02 Jagotec Ag Comprimé pharmaceutique flottant dans l'estomac destiné à la libération programmée du principe actif et procédé pour produire le matériel flottant compris dans le comprimé
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
ES2536836T3 (es) 2012-10-12 2015-05-29 Omya International Ag Formulación de medicamento gastrorretentivo y sistemas de liberación y su método de preparación usando carbonato de calcio transformado en funcional
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CA3084953A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Melanges non racemiques et leurs utilisations
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020247603A1 (fr) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations à libération modifiée et utilisations associées
WO2023214018A1 (fr) 2022-05-06 2023-11-09 Galenix Innovations Composition à libération prolongée gonflable à rétention gastrique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
FR2556964A1 (fr) * 1983-12-23 1985-06-28 Ile De France Nouvelles formes galeniques du sulpiride utilisables par voie orale
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
CA2039742A1 (fr) * 1990-04-23 1991-10-24 Andrew B. Dennis Comprimes pour ingredients pharmaceutiques sujets a problemes : composition et mode de preparation

Also Published As

Publication number Publication date
TNSN98049A1 (fr) 2005-03-15
NO995039L (no) 1999-12-17
NZ500288A (en) 2001-03-30
FR2762213A1 (fr) 1998-10-23
HUP0002455A3 (en) 2001-01-29
AR015586A1 (es) 2001-05-16
JP2001523241A (ja) 2001-11-20
ZA983258B (en) 1998-10-19
PL336273A1 (en) 2000-06-19
NO995039D0 (no) 1999-10-15
EP0983065A1 (fr) 2000-03-08
CA2286081A1 (fr) 1998-10-29
HUP0002455A2 (hu) 2000-12-28
WO1998047506A1 (fr) 1998-10-29
PE68199A1 (es) 1999-07-15
MA26482A1 (fr) 2004-12-20
FR2762213B1 (fr) 1999-05-14
CN1252720A (zh) 2000-05-10
IL131995A0 (en) 2001-03-19
AU7341698A (en) 1998-11-13
AU737634B2 (en) 2001-08-23
KR20010006353A (ko) 2001-01-26

Similar Documents

Publication Publication Date Title
EP0840606A4 (fr)
GB2282366B (en) Device for delivering an audible message
AP9801392A0 (en) Concentrated antibody preparation.
EP0662935A4 (fr) Generateur de gaz.
EP0646354A3 (fr) Dispositif autonome chirugical, actionné par une cartouche de gaz.
ZA987126B (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives.
EP0636617A3 (fr) Procédé pour la préparation de N-(2-hydroxyéthyle)pipérazine.
EP0659769A3 (fr) Agent pour promouvoir la prolifération de bifidobactérium.
JO2017B1 (en) Pharmaceutical formula for infectious residence
BG103714A (en) Pararacetamol-containing tablet
EP0449787A3 (en) Pharmaceutical, dietetic or veterinary compositions with eumetabolic activity
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DK1044064T3 (da) Overtrækningsindretning til granula til indtagelse ad oral vej
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
EP0607897A3 (en) Hydraulically-damped, active engine support.
FR2704931B1 (fr) Réservoir notamment bouteille de gaz.
HUT41002A (en) Process for preparing anticonvulsives
EP0646505A3 (fr) Dispositif générateur de gaz.
DE3674971D1 (en) P-acylaminobenzamide.
EP1018336A4 (fr) Carcinostatiques
TW348157B (en) Equipment and method to hold and to protect objects
IL116262A0 (en) Processes for preparing ranitidine
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance